Price History
Feb 9, 2026 — Aug 8, 2026Investment Snapshot
- Trading 58% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 5/9 — moderate financial health
- ROE of 15.5% — good return on equity
- Revenue declining 7% annually
Cabot Corporation Common Stock (CBT) is a Basic Materials company operating in Miscellaneous Chemical Products, listed on the NYSE , with a market capitalisation of $4.7 billion . Key value metrics: P/E ratio 19.1, P/B ratio 2.95, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Cabot Corporation Common Stock — Fundamental Analysis Summary
Cabot Corporation Common Stock (CBT) is currently trading 58% above its Graham Number of $57.96, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 19.1x.
On financial health, CBT shows a moderate Piotroski F-Score of 5/9, and solid return on equity of 15.5% (sector average: 0.2%), and manageable leverage with a debt-to-equity ratio of 0.63.
StockPik's composite Value Score for CBT is 74/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
CBT reports a moderate gross margin of 23.2% (sector average: 32.2%) and a solid operating margin of 14.3%.
CBT shows revenue declining at 7% year-over-year, with earnings declining at 13%.
CBT pays a modest dividend yield of 2.0%.